About Dream CIS
Dream CIS is a company based in Seoul (South Korea) founded in 2000. The company has 358 employees. Dream CIS offers products and services including Clinical Development, Medical Device Consulting, and Stand-alone Service. Dream CIS operates in a competitive market with competitors including Gentronix, Jade Bioscience, Tigermed, Shanghai Yaocheng Health Technology and ReveraGen, among others.
- Headquarter Seoul, South Korea
- Employees 358
- Stage Public
- SectorsHealthcare
- Website dreamcis.com
- Legal Name Dreamcis, Inc.
- Annual Revenue$46.14 M (USD)13.6as on Dec 31, 2025
- Net Profit$4.94 M (USD)34.97as on Dec 31, 2025
- EBITDA$5.59 M (USD)16.37as on Dec 31, 2025
- Employee Count358
Products & Services of Dream CIS
Dream CIS offers a comprehensive portfolio of products and services, including Clinical Development, Medical Device Consulting, and Stand-alone Service.
Provides development for clinical trials in various areas
Offers advisory for medical devices and trials
Delivers independent clinical support services
IPO & Listings of Dream CIS
Dream CIS is a publicly listed company on the KRX with ticker symbol 223250 in South Korea, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date22 May 2020
- Listed onKRX: 223250
- Listed entityDreamCIS, Inc.
- Exchange sectorCommercial services
- ISINKR7223250002
- Share price3,880.00 KRW (+0.13% on the day) · 2026-10-08
- Market capitalisation95,449,718,399.00 KRW
- Price to earnings213.3
- EPS (diluted, trailing year)18.19 KRW
- Volume (last session)374,547
Financials of Dream CIS
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 66.63B KRW | 7.13B KRW | 8.07B KRW |
| 2024 | 58.65B KRW | 5.28B KRW | 6.93B KRW |
| 2023 | 47.84B KRW | 3.74B KRW | 3.74B KRW |
| 2022 | 38.87B KRW | 4.41B KRW | 7.64B KRW |
| 2021 | 26.15B KRW | 3.23B KRW | 4.62B KRW |
Detailed financial statements for Dream CIS
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Competitors of Dream CIS
Dream CIS operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Gentronix, Jade Bioscience, Tigermed, Shanghai Yaocheng Health Technology and ReveraGen, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| gentronix.co.uk | 1999 | Alderley Edge, United Kingdom | $3.84M | 1 | In-vitro and in-vivo genetic toxicology screening services are provided. | |
| jadebioscience.in | 2020 | Vapi, India | – | – | Provides toxicology, chemistry, and consultancy services for agrochemical industries. | |
| tigermedgrp.com | 2004 | Hangzhou, China | – | 15 | Drug development and preclinical services are provided by Tigermed. | |
| yaocheng.cn | 2020 | Shanghai, China | $15.44M | – | Clinical trial services to biopharma sector are provided. | |
| reveragen.com | 2008 | Rockville, United States | – | – | Steroids for Duchenne muscular dystrophy treatment are developed. | |
| aquila-bm.com | 2011 | Edinburgh, United Kingdom | – | 489 | Preclinical services in immunology, regeneration, neuroscience, and histology are provided. | |
| bioqual.com | 1981 | Rockville, United States | – | 193 | Contract research on infectious disease models is conducted. | |
| phaxiam.com | 2004 | Lyon, France | $15.8M | – | Antibacterial treatments using bacteriophages are developed for resistant infections. | |
| simrbio.com | 2014 | Shanghai, China | $20.76M | – | Diversified preclinical services for brain-related disorders are provided. |
Detailed competitors of Dream CIS
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Dream CIS
The website of Dream CIS (dreamcis.com) receives about 67.9K visits a month.
- Monthly visits67.9K
▲ 11.8% vs previous month
Latest news on Dream Cis
Complete news archive for Dream CIS
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Dream CIS
10 companies that operate in the same segment as Dream CIS (Biopharma Outsourcing & Drug Delivery), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of integrated contract research development and manufacturing services | 2007 | Bengaluru, Karnataka, India | USD 35.74 M | USD 226.38 M | 1,820 | |
Drug discovery and development services are provided to biopharma sector. | 1993 | Hamburg, Hamburg, Germany | USD 25 M | USD 926.33 M | 4,830 | |
Drug discovery and development services for small molecules are provided. | 2003 | Beijing, China | USD 320 M | – | 476 | |
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 255.15 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Pharmaceutical and biotechnology company | 2005 | Hyderabad, Telangana, India | USD 229.73 M | USD 726.15 M | 12,470 | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | New York, New York, United States | USD 8 M | USD 266.99 M | 1,770 | |
Provider of laboratory tests for physicians | 1969 | Burlington, Vermont, United States | – | USD 13.95 B | 70,000 | |
India's leading healthcare products distribution platform | 2018 | Mumbai, Maharashtra, India | USD 59.67 M | USD 702.49 M | 4,260 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Dream CIS
Dream CIS was founded in 2000.
Dream CIS is headquartered in Seoul, South Korea.
Dream CIS has 358 employees.
Annual revenue of Dream CIS is $46.14M as on Dec 31, 2025.
Dream CIS was founded in 2000 and is based in Seoul, South Korea. Clinical research services are offered by the company within the healthcare sector. Operations include support for trial management, data collection, and regulatory compliance. Focus is placed on pharmaceutical and biotech clients. Activities are conducted primarily in the Asia-Pacific region, with emphasis on efficient research processes.
Dream CIS's top competitors include PHAXIAM, BioQual and Jade Bioscience.
Dream CIS offers Clinical Development, Medical Device Consulting, and Stand-alone Service.
Yes, Dream CIS is publicly traded on KRX under the ticker symbol 223250.
Dream CIS operates through Dreamcis Co., Ltd..